These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 25691681

  • 1. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study Group.
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [Abstract] [Full Text] [Related]

  • 2. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM.
    Nephrol Dial Transplant; 2017 Nov 01; 32(11):1918-1926. PubMed ID: 28339993
    [Abstract] [Full Text] [Related]

  • 3. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
    Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A.
    Nephrol Dial Transplant; 2017 Aug 01; 32(8):1330-1338. PubMed ID: 27342579
    [Abstract] [Full Text] [Related]

  • 4. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL, Plosker GL.
    Drugs; 2015 Apr 01; 75(5):533-42. PubMed ID: 25761962
    [Abstract] [Full Text] [Related]

  • 5. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A, Al-Makki A, Sutton J, Shepler B.
    Clin Ther; 2014 Dec 01; 36(12):2082-2093. PubMed ID: 25450474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.
    Nephrol Dial Transplant; 2019 Jul 01; 34(7):1163-1170. PubMed ID: 29846719
    [Abstract] [Full Text] [Related]

  • 8. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW, Sprague SM, Vervloet M, Ramos R, Kalantar-Zadeh K.
    J Nephrol; 2022 Apr 01; 35(3):875-888. PubMed ID: 35138627
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
    Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A.
    Hemodial Int; 2018 Oct 01; 22(4):480-491. PubMed ID: 29656600
    [Abstract] [Full Text] [Related]

  • 10. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, PA21 Study Group.
    Kidney Int; 2014 Sep 01; 86(3):638-47. PubMed ID: 24646861
    [Abstract] [Full Text] [Related]

  • 11. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM, Floege J.
    Expert Opin Pharmacother; 2018 Jul 01; 19(10):1137-1148. PubMed ID: 29985725
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study.
    Liu J, Zuo L, Walpen S, Bernard L, Marty M, Enoiu M.
    Nephron; 2024 Jul 01; 148(1):22-33. PubMed ID: 37473746
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O, Maillard M, Malluche HH, Stehle JC, Funk F, Burnier M.
    Biomed Res Int; 2015 Jul 01; 2015():515606. PubMed ID: 26221597
    [Abstract] [Full Text] [Related]

  • 17. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F, Terao A.
    Clin Exp Nephrol; 2017 Jun 01; 21(3):513-522. PubMed ID: 27389681
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
    Koiwa F, Yokoyama K, Fukagawa M, Akizawa T.
    J Ren Nutr; 2017 Sep 01; 27(5):346-354. PubMed ID: 28550969
    [Abstract] [Full Text] [Related]

  • 19. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R, Chazot C, Ferreira A, Di Benedetto A, Gurevich K, Feuersenger A, Wolf M, Arens HJ, Walpen S, Stuard S.
    BMC Nephrol; 2020 Dec 07; 21(1):530. PubMed ID: 33287733
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacological, pharmaceutical and clinical profiles of sucroferric oxyhydroxide (P-TOL® Chewable Tab. 250 mg, 500 mg), a therapeutic agent for hyperphosphatemia].
    Tatemichi S, Nakagaki F, Yoshioka S, Shichiri N.
    Nihon Yakurigaku Zasshi; 2018 Dec 07; 151(2):75-86. PubMed ID: 29415929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.